Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
3.02 HKD +0.33% Intraday chart for Sino Biopharmaceutical Limited -4.13% -12.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 CI
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China MT
Sino Biopharmaceutical's Developing Two Drugs for MASH MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy MT
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" CI
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR MT
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet CI
Hong Kong Shares Slump Amid Chinese Growth Concerns MT
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart CI
Sino Biopharmaceutical's Anti-Cancer Drug Under Priority Review in China MT
Sino Biopharm Units Sell 67% Stake in Pharmaceutical Company MT
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 million RE
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical Co., Ltd from Sino Biopharmaceutical Limited for CNY 1.8 billion. CI
Sino Biopharmaceutical Files for Chinese Launch of Obeticholic Acid Tablets MT
China Outlook, Profit-Taking Roil Asian Stock Markets MT
Sino Biopharmaceutical Repurchases Over 78 Million Shares Under Buyback Plan MT
Sino Biopharm's Lung Cancer Drug Added to China's Priority List for Evaluation MT
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) CI
Sino Biopharmaceutical Trustee Buys Back 2 Million Shares MT
Sino Biopharmaceutical Trustee Repurchases Shares MT
Chinese Regulator Grants Marketing Approval for Sino Biopharmaceutical’s Immune Thrombocytopenia Drug MT
Sino Biopharm Begins Phase 3 Trial for Type 2 Diabetes Injectable; Shares Fall 4% MT
Sino Biopharmaceutical Trustee Repurchases 5 Million Shares MT
Sino Biopharmaceutical’s Trustee Buys Back Shares MT
Chart Sino Biopharmaceutical Limited
More charts
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
2.789 CNY
Average target price
4.489 CNY
Spread / Average Target
+60.95%
Consensus
  1. Stock
  2. Equities
  3. Stock Sino Biopharmaceutical Limited - Hong Kong S.E.
  4. News Sino Biopharmaceutical Limited
  5. Market Chatter: Third Person in Hong Kong Dies After Getting Sinovac Jab